Biological Products, (No Diagnostic Substances)
| Institution | Shares | Value | Ownership % | Change | Filing Date |
|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | 17.75M | $43.0M | 9.83% | -- | 2026-06-30 |
| TCG Crossover Management, LLC | 17.75M | $43.0M | 9.83% | -- | 2026-06-30 |
| Versant Venture Management, LLC | 12.17M | $29.0M | 6.74% | -- | 2026-06-30 |
| Deep Track Capital, LP | 9.46M | $23.0M | 5.24% | -25.1K | 2026-06-30 |
| Venrock Adviser, LLC | 8.70M | $21.0M | 4.82% | -- | 2026-06-30 |
| RTW INVESTMENTS, LP | 8.70M | $21.0M | 4.82% | -- | 2026-06-30 |
| Commodore Capital LP | 8.70M | $21.0M | 4.82% | -- | 2026-06-30 |
| BlackRock, Inc. | 8.09M | $19.0M | 4.48% | +6.57M | 2026-06-30 |
| VANGUARD CAPITAL MANAGEMENT LLC | 5.70M | $13.0M | 3.16% | +17.5K | 2026-06-30 |
| Balyasny Asset Management L.P. | 5.52M | $13.0M | 3.06% | +505.2K | 2026-06-30 |
